Comparison of the various diagnostic criteria used in polycystic ovary syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20221933Keywords:
Hyperandrogenism, Polycystic ovary syndrome, RotterdamAbstract
Background: Polycystic Ovary Syndrome (PCOS) represents one of the major causes of infertility in women. Various criteria are set to diagnose PCOS, some over diagnose and some underdiagnose it. The objective of the study was to compare the various criteria used for the diagnosis of PCOS: NIH 1990 criteria, Rotterdam 2003 criteria and AE-PCOS Society 2006 criteria.
Methods: This was a cross-sectional study conducted over a period of one year. Patients with suspicion of PCOS were selected. After complete history and examination, blood samples were collected and androgen levels were measured. They were labeled as PCOS based on their fulfillment of the criteria as per Rotterdam, NIH and AE-PCOS Society.Data was analysed and conclusions drawn.
Results: Of the participants, 25.7%, 28.5%, and 62.8% were diagnosed with PCOS using NIH, AE-PCOS Society, and Rotterdam criteria, respectively. Phenotypes that included hyperandrogenism and/or hyperandrogenemia as part of their criteria showed increase in values of DHEAS and S. testoterone as compared to the normoandrogenic phenotype included in only the Rotterdam criteria.
Conclusions: It is crucial to establish the diagnostic criteria for PCOS and initiate early treatment as this may play a role in the prevention of metabolic and cardiovascular diseases.
References
Hestiantoro A, Hasani KRD, Shadrina A. Body fat percentage is a better marker than body mass index for determining inflammation status in polycystic ovary syndrome. Int J Reprod Biomed (Yazd). 2018;16(10):623-8.
NIH Office of Disease Prevention. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. 2012 Expert Panel Guidelines on PCOS. Available at: https://prevention.nih.gov/docs/programs/ pcos/FinalReport.pdf. Accessed on 5th December 2012.
Alexiou E, Hatziagelaki E, Pergialiotis V, Chrelias C, Kassanos D, Siristatidis C, et al. Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index. Horm Mol Biol Clin Investig. 2017;29(3):105-11.
Abinaya S, Siva D, Sabitha R, Achiraman S. An Overview of Hyperandrogenism in PCOS and the Prospective Underlying Factors RJLBPCS. Life Science Informatics Publications. 2019;5(1):179.
Ribeiro VB, Kogure GS, Lopes IP. Association of measures of central fat accumulation indices with body fat distribution and metabolic, hormonal, and inflammatory parameters in women with polycystic ovary syndrome. Arch Endocrinol Metab. 2019;63(4):417-26.
Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q. Anthropometric and Biochemical Characteristics of Polycystic Ovarian Syndrome in South Indian Women Using AES-2006 Criteria. Int J Endocrinol Metab. 2014;12(1):e12470.
Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467-520.
Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019;23(3):326-31.
Głuszak O, Stopińska-Głuszak U, Glinicki P, Kapuścińska R, Snochowska H, Zgliczyński W, et al. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol. 2012;2012:569862.
Pehlivanov B, Orbetzova M. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecol Endocrinol. 2007;23(10):604-9.
Barth JH, Field HP, Yasmin E, Balen AH. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur J Endocrinol. 2010;162(3):611-5.